HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 08-18-2019, 05:14 PM   #1
Cathya
Senior Member
 
Cathya's Avatar
 
Join Date: Sep 2005
Location: Ontario, Canada
Posts: 751
Breast cancer drug could replace traditional chemotherapy for certain patients

Promising breast cancer drug could reshape treatment

Ian Krop. Study finds drugs that can overcome drug resistance in HER2-positive breast cancer

By ALEXI COHAN | alexi.cohan@bostonherald.com | Boston Herald
PUBLISHED: June 15, 2019 at 7:23 pm | UPDATED: June 15, 2019 at 9:10 pm

A breast cancer drug with the potential to replace traditional chemotherapy is accelerating through clinical development and could soon offer patients who previously had limited options an effective treatment.

Over 400,000 people are diagnosed with HER2-positive breast cancer each year, a type of cancer that learns to resist the drugs designed to attack it. Women with HER2 can start by taking the breast cancer drug Herceptin, then often move to Kadcyla once the cancer becomes resistant.

After the disease overpowers Kadcyla, there is no standard course of action, according to Dr. Ian Krop, clinical research director of the Breast Oncology Center at Dana-Farber Cancer Institute.

That’s where the DS-8201 cancer treatment, developed by Japanese company Daiichi Sankyo, comes in.

The drug works by attaching chemotherapy to antibodies that offer a targeted attack on cancer cells and milder side effects compared to traditional chemotherapy.

Krop said that in clinical trials, 90% of patients saw some degree of tumor shrinkage. The treatment has also been seen to double survival time for advanced breast cancer patients to 20 months from 10 months.

Krop called the results “precedent-setting.”

“People run out of treatments that work eventually and then we are kind of stuck,” said Krop. “What’s really kind of special about this new drug is that it seems to start working when all the other drugs have stopped working.”

“I think this drug can definitely replace chemotherapy,” said Krop.


Clinical trials of DS-8201 started at Dana-Farber three years ago and Krop has seen the results in his own patients, some who travel a great distance for access to the treatment.

“It’s been a great experience to be involved with this because it looks like it will be a real breakthrough for these patients,” said Krop. He added that his patient’s pain levels and symptoms have improved while on the drug and CAT scans show the cancer has regressed considerably.

Krop said there are still some side effects for patients taking DS-8201, like hair loss, some nausea and some lowering of blood counts, however they are more mild than the side effects of traditional chemotherapy.

Cheryl Osimo, a breast cancer survivor and executive director of the Massachusetts Breast Cancer Coalition, knows the devastating side effects of chemotherapy all too well.

“My chemotherapy affected my vision. I lost all my hair. For some women, it affects every part of their being, every part of their body,” said Osimo. “It can be debilitating because you feel nauseous a lot.”

Osimo said, “A treatment that has milder effects and is more effective can provide people with hope, once you run out of treatment options … you become hopeless, so the more options the better.”

Daiichi Sankyo is currently accelerating its biologics license application, meaning that the drug could be approved by the Food and Drug Administration sooner than expected. Krop said it could be approved sometime in 2020.

Krop said looking toward the future, DS-8201 also has the potential to work in lung or stomach cancers.

The breakthrough drug is also expected to prompt major changes in the market as the company announced it will partner with AstraZeneca to develop and commercialize DS-8201 in many countries worldwide. The deal sees AstraZeneca paying Daiichi Sankyo up to $6.9 billion in total.
__________________
Cathy

Diagnosed Oct. 2004 3 cm ductal, lumpectomy Nov. 2004
Diagnosed Jan. 2005 tumor in supraclavicular node
Stage 3c, Grade 3, ER/PR+, Her2++
4 AC, 4 Taxol, Radiation, Arimidex, Actonel
Herceptin for 9 months until Muga dropped and heart enlarged
Restarting herceptin weekly after 4 months off
Stopped herceptin after four weekly treatments....score dropped to 41
Finished 6 years Arimidex
May 2015 diagnosed with ovarian cancer
Stage 1C
started 6 treatments of carboplatin/taxol
Genetic testing show BRCA1 VUS
Nice! My hair came back really curly. Hope it lasts lol. Well it didn't but I liked it so I'm now a perm lady
29 March 2018 Lung biopsy following chest CT showing tumours in pleura of left lung, waiting for results to the question bc or ovarian
April 20, 2018 BC mets confirmed, ER/PR+ now Her2-
Questions about the possibility of ovarian spread and mets to bones so will be tested and monitored for these.
To begin new drug Palbociclib (Ibrance) along with Letrozole May, 2018.
Genetic testing of ovarian tumour and this new lung met will take months.
To see geneticist to be retested for BRCA this week....still BRCA VUS
CA125 has declined from 359 to 12 as of Aug.23/18


Cathya is offline   Reply With Quote
Old 08-18-2019, 09:15 PM   #2
Bunty
Senior Member
 
Join Date: Jul 2011
Location: Sydney, Australia
Posts: 461
Re: Breast cancer drug could replace traditional chemotherapy for certain patients

Thanks Cathy! It's always heartening to read of these potential new drugs. I wonder if anyone on the board here is on DS-8201?
Cheers Marie
Bunty is offline   Reply With Quote
Old 08-19-2019, 02:45 PM   #3
tricia keegan
Senior Member
 
tricia keegan's Avatar
 
Join Date: Nov 2005
Location: Ireland
Posts: 3,428
Re: Breast cancer drug could replace traditional chemotherapy for certain patients

Thanks Cathy, it's so promising to see so many new drugs becoming available, lets hope that continue's.
__________________
Tricia
Dx July '05 IDC 1.9cm Triple positive 3/9 nodes positive
A/C X 4 ..Taxol/Herceptin x 12 wks then herceptin 1 yr
Rads x 36 ..oophorectomy August '06
Currently taking Arimidex..
June 2011 osteopenia/ zometa x1 yearly- stopped Zometa 2015 as Dexa show normal bone density.
Stopped Arimidex July 2014- Restarted Arimidex 2015 for a further two years on the advice of my Onc.
2014 Normal Dexa scan
2018 Mammo all clear, still NED!
tricia keegan is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 09:54 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter